AstraZeneca will test using component of Russia’s Sputnik V in clinical trials of its own vaccine against coronavirus

• Sputnik V is one of the most effective vaccines globally with over 90% efficacy against coronavirus. The unique feature of the Russian vaccine is the use of two different components based on human adenovirus in two separate inoculations in order to deliver genetic material from the spike of the coronavirus into the human body. This approach provides for a stronger and longer-term immune response compared with vaccines using the same component for both inoculations.
• On November 23, 2020, following results which showed high efficacy for the Sputnik V vaccine, RDIF and the Gamaleya Center offeredAstraZeneca the use of one of the two components of the Sputnik V vaccine.
• AstraZenecaacceptedthe proposal by RDIF and the Gamaleya Center to use one of the two vectors of the Sputnik V vaccine in additional clinical trials of its own vaccine, which will commence before the end of this year.

Moscow, December 11 2020 –After the Sputnik V vaccine’s clinical trial preliminary results showed its efficacy at above 90 percent, the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Gamaleya Institute on November 23, 2020 offeredAstraZenecatouseone of the two components (humanadenoviralvectors[1]) of the Sputnik V vaccine in AstraZeneca’s clinical trials.

AstraZenecaaccepted RDIF’s proposal and will begin clinical trials of its vaccine in combination with Sputnik V’s human adenoviral vector type Ad26 by the end of 2020. ThisresearchwillallowAstraZeneca’s scientists to study the possibility of boosting their vaccine’s efficacy through the application of this combined approach.

Sputnik V is among the world’s most effective and safe vaccines due to its unique technology combining two different human adenoviral vectors providing for a stronger and longer-term immune response compared to vaccines using the same component for both inoculations[2].

The regimen with two different adenoviral vectors for a prime and a boost immunization is a unique and ground-breaking discovery of the GamaleyaCenter scientists. It helps to completely avoid immunity to the first vector, which forms after the first inoculation and thus to raise efficacy and create long-term immunity. Among the leading COVID-19 vaccines only Sputnik V is using the two-vector technology.

RDIF’sofferto AstraZeneca was an example of Russia’s proactive approach: it has not only to create one of the world’s most effective vaccines to date against coronavirus but is ready to share SputnikVvectorswith those willing to produce vaccines using the two-vector technology.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented:

“This unique example of cooperation between scientists from different countries in jointly fighting coronavirus will play a decisive role in achieving a final victory over the pandemic globally. Russia’s Sputnik V vaccine is already saving people’s lives in Russia today through a large-scale vaccination program. The decision by AstraZeneca to carry out clinical trials using one of two vectors of Sputnik V in order to increase its own vaccine’s efficacy is an important step towards uniting efforts in the fight against the pandemic. We welcome the beginning of this new stage of cooperation between vaccine producers. We are determined to develop this partnership in the future and to start joint production after the new vaccine demonstrates its efficacy in the course of clinical trials. We hope that other vaccine producers will follow our example.”

[1]Human adenoviral vector is a common cold virus, which has been with humankind for over 100 000 years. It lacks a gene responsible for reproduction and is used to transport into a cell genetic material from another virus that is being vaccinated against, in this case, SARS-COV-2 which causes novel coronavirus infection. The vector as well as genetic material inside it do not pose any hazard to the body.

[2] For example, Pfizer, AstraZeneca, Moderna, Johnson&Johnson as well as other two-dose vaccine producers use the same component for both inoculations in their vaccines.